Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.
about
Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
P2860
Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Moving Beyond Maximum Tolerate ...... in Multiple Myeloma Patients.
@en
Moving Beyond Maximum Tolerate ...... in Multiple Myeloma Patients.
@nl
type
label
Moving Beyond Maximum Tolerate ...... in Multiple Myeloma Patients.
@en
Moving Beyond Maximum Tolerate ...... in Multiple Myeloma Patients.
@nl
prefLabel
Moving Beyond Maximum Tolerate ...... in Multiple Myeloma Patients.
@en
Moving Beyond Maximum Tolerate ...... in Multiple Myeloma Patients.
@nl
P2093
P2860
P356
P1476
Moving Beyond Maximum Tolerate ...... in Multiple Myeloma Patients.
@en
P2093
P2860
P304
P356
10.1002/CPT.712
P407
P577
2017-04-17T00:00:00Z